Height as a potential indicator of early life events predicting parkinson's disease: A case-control study

Movement Disorders

Volumn 22, Issue 15, 2007, Pages 2263-2267

  Ragonese, Paolo ^a   D'Amelio, Marco ^a   Callari, Graziella ^a   Aiello, Fabio ^a   Morgante, Letterio ^b   Savettieri, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Anthropometric measures; Epidemiology; Height; Parkinson's disease; Risk factors

Indexed keywords

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY GROWTH; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; FEMALE; HEIGHT; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIFE EVENT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; BODY HEIGHT; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 38049073281     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21728     Document Type: Article

References (24)

1. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast Cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2004;111:762-771.
2. Bell W, Davies JS, Evans WD, Scanlon MF, Mullen R. Somatic characteristics and cardiovascular risk factors in growth hormone deficiency: a randomized, double-blind, placebo-controlled study of the effect of treatment with recombinant human growth hormone. Am J Hum Biol 2004;16:533-543.
3. Bercu BB, Diamond FB, Jr. Growth hormone neurosecretory dysfunction. Clin Endocrinol Metab 1986;15:537-590.
4. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol 2002;31:285-293.
5. Crespi F. Functional in vivo interaction between growth hormone and dopamine systems are correlated to changes in striatal somatostatin levels as detected by voltammetry. Exp Brain Res 1993; 94:363-370.
6. Miyake H, Nagashima K, Onigata K, Nagashima T, Takano Y, Morikawa A. Allelic variations of the D2 dopamine receptor gene in children with idiopathic short stature. J Hum Genet 1999;44: 26-29.
7. Arinami T, Iijima Y, Yamakawa-Kobayashi K, et al. Supportive evidence for contribution of the dopamine D2 receptor gene to heritability of stature: linkage and association studies. Ann Hum Genet 1999;63 (Part 2):147-151.
8. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1992;42:1901-1907.
9. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997;48:1277-1281.
10. Venn A, Bruinsma F, Werther G, et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 2004;364:1513-1518.
11. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001;16:830-837.
12. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004;62:2010-2014.
13. Popat RA, van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005;65:383-390.
14. Chen H, Zhang SM, Schwarzschild MA, et al. Obesity and the risk of Parkinson's disease. Am J Epidemiol 2004;159:547-555.
15. Abbott RD, Ross GW, White LR, et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology 2002;59:1051-1057.
16. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
17. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol 1994;40:111-116.
18. Cuneo RC, Judd S, Wallace JD, et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998;83:107-116.
19. Fernald LC, Grantham-McGregor SM. Growth retardation is associated with changes in the stress response system and behavior in school-aged Jamaican children. J Nutr 2002;132:3674-3679.
20. Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000;55:1350-1358.
21. Ragonese P, Salemi G, Morgante L, et al. A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease. Neuroepidemiology 2003;22:297-304.
22. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
23. Finch CE, Crimmins EM. Inflammatory exposure and historical changes in human life-spans. Science 2004;305:1736-1739.
24. Beeri MS, Davidson M, Silverman JM, Noy S, Schmeidler J, Goldbourt U. Relationship between body height and dementia. Am J Geriatr Psychiatry 2005;13:116-123.